Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

eISSN: 1178-7007pISSN: 1178-7007
JournalOpen Access

Journal formatting to fit the target journal guidelines

Experts ensure all elements of your paper match journal formatting guidelines to improve publication success rate!

Key Metrics

CiteScore
3.5
Scite Index
0.84 5-Year SI
SJR
Q3Pharmacology
SNIP
0.92
3
Time to Publish
time-to-publish View Chart
4  Mo

Journal Specifications

Indexed in the following public directories

  • Web of Science
  • Scopus
  • DOAJ
  • SJR
Overview
  • Publisher
    DOVE MEDICAL PRESS LTD
  • Language
    English
  • Frequency
    Continuous publication
  • Article Processing Charges
    USD 2836
  • Publication Time
    16
  • Editorial Review Process
    Anonymous peer review
General Details
Publication Details
Editorial Review Detail
Information for authors
View less

Ready to spotlight your research findings?

Impress peers and journals alike with a concise, visual summary of your work.

check-iconMeets Top Publisher Standards: Essential for leading journals like Elsevier.
check-iconEnhances Engagement: Research papers with graphical abstracts receive 3X more downloads and 8X more shares.
check-iconTailored Just for You: We’ll create a custom graphical abstract based on your manuscript—no sketches needed.
Learn morethumb-icon 3000+ graphical abstracts produced with 4.8/5 customer rating
Time to Publish
Time to publish distribution
Articles published in year 2022
Time to publish index
Months% Papers published
0-3 23%
4-6 67%
7-9 9%
>9 1%

Topics Covered

Obesity
Type 2 diabetes
Liver disease
Curcumin
Metabolic syndrome
Insulin resistance
Cross-sectional study
Overweight
Western blot
Randomized controlled trial
Berberine
Psoriasis
Fatty liver
Anemia
Type 2 Diabetes Mellitus
Blood pressure
Electromagnetic field
Oxidative stress
Melanoma
Metformin

Year-wise Publication

FAQs

Since when has Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy been publishing? Faqs

The Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy has been publishing since 2008 till date.

How frequently is the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy published? Faqs

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is published Continuous publication.

Who is the publisher of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy? Faqs

The publisher of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is DOVE MEDICAL PRESS LTD.

How can I view the journal metrics of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy on editage? Faqs

For the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy metrics, please refer to the section above on the page.

What is the eISSN and pISSN number of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy? Faqs

The eISSN number is 1178-7007 and pISSN number is 1178-7007 for Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.

What is the focus of this journal? Faqs

The journal covers a wide range of topics inlcuding Obesity, Type 2 diabetes, Liver disease, Curcumin, Metabolic syndrome, Insulin resistance, Cross-sectional study, Overweight, Western blot, Randomized controlled trial, Berberine, Psoriasis, Fatty liver, Anemia, Type 2 Diabetes Mellitus, Blood pressure, Electromagnetic field, Oxidative stress, Melanoma, Metformin.

Why is it important to find the right journal for my research? Faqs

Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.

Can the choice of journal affect my academic career? Faqs

Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.

Is it advisable to target high-impact journals only? Faqs

While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.